Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
47.14
+0.45 (0.96%)
At close: Sep 5, 2025, 4:00 PM
47.00
-0.14 (-0.30%)
After-hours: Sep 5, 2025, 7:56 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $12.27B in the quarter ending June 30, 2025, with 0.56% growth. This brings the company's revenue in the last twelve months to $47.70B, up 2.57% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.70B
Revenue Growth
+2.57%
P/S Ratio
2.01
Revenue / Employee
$1,398,944
Employees
34,100
Market Cap
95.95B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BMY News
- 15 hours ago - Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly - Seeking Alpha
- 1 day ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 2 days ago - Bristol-Myers Squibb: Not As Cheap As It Might Seem - Seeking Alpha
- 4 days ago - 7 Big Yields From The Beat-Up Healthcare Sector - Forbes
- 5 days ago - 8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report - Seeking Alpha
- 7 days ago - Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 - Business Wire
- 7 days ago - Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 8 days ago - 8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars - Seeking Alpha